Quotes 5-day view Delayed Nyse
01/23/2023
01/24/2023
01/25/2023
01/26/2023
01/27/2023
Date
109.88(c)
108.52(c)
108.59(c)
106.87(c)
105.38(c)
Last
8 998 829
7 424 168
6 167 973
9 672 675
7 784 913
Volume
-0.05%
-1.24%
+0.06%
-1.58%
-1.39%
Change
Estimated financial data (e) (USD)
Sales 2022
59 119 M
-
-
Net income 2022
14 779 M
-
-
Net Debt 2022
17 558 M
-
-
P/E ratio 2022
17,9x
Yield 2022
2,65%
Sales 2023
58 162 M
-
-
Net income 2023
16 627 M
-
-
Net Debt 2023
9 650 M
-
-
P/E ratio 2023
15,8x
Yield 2023
2,82%
Capitalization
267 B
267 B
-
EV / Sales 2022
4,82x
EV / Sales 2023
4,76x
Nbr of Employees
67 500
Free-Float
70,8%
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (87.8%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of...
Ratings of Merck & Co., Inc.
All news about MERCK & CO., INC.
News in other languages on MERCK & CO., INC.
Analyst Recommendations on MERCK & CO., INC.
ETFs positioned on MERCK & CO., INC. ETFs and Trackers with Trackinsight
Momentum Picks: 5 stocks for the fall
MERCK & CO., INC. A cash cow that hides some gems
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends MERCK & CO., INC.
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
105,38 $
Average target price
116,38 $
Spread / Average Target
10,4%
Please enable JavaScript in your browser's settings to use dynamic charts.